Purchase this article with an account.
M.L. Nelson, A. Martidis, D.J. Spinak, M. Liu, A. Sivalingam, J.L. Federman; Intravitreal Triamcinolone for Refractory Pseudophakic Cystoid Macular Edema . Invest. Ophthalmol. Vis. Sci. 2003;44(13):226.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: Evaluate the effectiveness of intravitreal triamcinolone acetonide in the treatment of refractory pseudophakic cystoid macular edema Methods: Records of fifteen patients treated with intravitreal triamcinolone acetonide for postoperative pseudophakic CME unresponsive to conventional therapy were analyzed retrospectively. Results: Sixteen eyes in fifteen patients had refractory pseudophakic CME that was treated with 4mg of intravitreal triamcinolone acetonide. Mean visual acuity improved an average of 3.0 lines (range 0-5 lines). Average follow-up was 5.6 months. One eye required retreatment. Four eyes received optical coherence tomography (OCT) before and after treatment. Retinal thickness decreased an average of 42% in these four eyes. Four eyes required treatment with topical ocular hypotensives due to a steroid response. One eye had a retinal detachment, which was successfully managed. Conclusions: Intravitreal triamcinolone acetonide appears to be a promising treatment for eyes with refractory pseudophakic CME. Further study is warranted to determine long-term efficacy and safety.
This PDF is available to Subscribers Only